CNDAC is an orally available deoxycytosine nucleoside analog with potential antineoplastic activity. Upon administration, CNDAC is phosphorylated to generate its nucleotide form, functioning as a deoxycytosine mimic and is incorporated into DNA in tumor cells. This causes DNA strand breaks during polymerization due to beta-elimination during the fidelity checkpoint, resulting in G2/M phase-arrest and tumor cell apoptosis.

KEYWORDS: CNDAC hydrochloride | Supplier | DNA damage and apoptosis inducer | DFP-10917 hydrochloride | TAS-109 hydrochloride | DFP10917 | DFP 10917 | TAS109 | TAS 109 | CT-CNDAC | CAS [134665-72-8] | [135598-68-4] | Adenosine | Non Selective | Inhibitor | Unclassified